<DOC>
	<DOCNO>NCT02661477</DOCNO>
	<brief_summary>The study investigate efficacy safety subcutaneous interferon alpha -2a eradicate rhinovirus patient primary hypogammaglobulinemia . Patients hypogammaglobulinemia persistent rhinovirus infection . Rhinovirus may worsen pulmonary complication . Pegylated interferon alpha ribavirin appear effectively clear persistent rhinovirus infection hypogammaglobulinemia patient . Patients primary hypogammaglobulinemia confirm respiratory rhinovirus infection randomly assign double-blind fashion receive either - Group 1 : subcutaneous pIFNÎ±2a - Group 2 : subcutaneous placebo Subjects schedule study visit 1-week 2-month entry study . In addition , possible bacterial infection treat antibiotic . Each patient follow weekly nasal surveillance sample 2 month symptom diary . Blood draw take place study entry , 1-week 2-month time-points .</brief_summary>
	<brief_title>Clinical Virological Efficacy Pegylated Interferon Alpha Treatment Rhinovirus Infection Patients With Primary Hypogammaglobulinemia : Randomized Controlled Trial</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Agammaglobulinemia</mesh_term>
	<mesh_term>Common Variable Immunodeficiency</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Adult patient ( &gt; 18 year ) , primary hypogammaglobulinemia regular immunoglobulin replacement therapy , rhinovirus positive nasal swab , thrombocytes 90 x109/L , Neutrophiles &gt; 1,5 x109/L write informed consent . Participation another study , need intensive care unit treatment , difficulty understand national language , pregnancy breastfeeding , somatic , psychiatric social disease issue opinion investigator make participation trial best interest subject .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>